7 results
P
patients with nasopharyngeal carcinoma (NPC)
I/C
pre and post-Epstein Barr Virus (EBV) DNA load testing, high pre and post-EBV DNA levels vs. low pre and post-EBV DNA levels
O
survival outcomes, including overall survival (OS), disease free survival (DFS), progression-free survival (PFS), distant-metastasis-free survival (DMFS), and local-regional-failure-free survival (LRFS)
P
patients with Sjögren's syndrome (SjS), healthy controls
I/C
serological study, systematic review and meta-analysis, IgG-anti-EA antibody positivity, high titers of IgG-anti-EA antibody, titer of IgG-anti-VCA antibody, C3 levels, C4 levels
O
association between EBV infection and SjS, obvious associations of SjS with IgM-anti-VCA antibody and IgG-anti-EA antibody, link between IgG-anti-EA antibody and low levels of C3 and C4
P
patients with multiple sclerosis (MS)
I/C
EBV antibodies to the nuclear antigen (EBNA1) and viral capsid antigen (VCA), clinical disease markers including conversion from CIS to RRMS, neurological disability, or disease phenotype
O
inflammatory disease activity as assessed by gadolinium-enhancing Magnetic Resonance Imaging (MRI) lesions, decrease in EBV levels following initiation of certain disease-modifying therapies
P
Osteoarthritis, DIOs, selenium
I/C
bioinformatic techniques, database, network analysis, healthy individuals, OA patients
O
expression of DIOs, thyroid hormone receptor, iodothyronine
P
Italy
I/C
infections, other developed countries
O
7.6% of cancer deaths and 6.9% of incident cases attributable to infections
P
pre-treated RM-NPC patients
I/C
Cell-based Immunotherapy (CBI), standard second-line chemotherapy
O
objective response rate (ORR), progression-free survival (PFS), median overall survival (OS)
P
Shenmai injection, granulocytopenia, oncology patients
I/C
red ginseng, ophiopogon japonicus, control group
O
efficiency, post-treatment leukocyte count